BPX-701

N/A

Report date: 2023/10/06 20:05:25

Base Information

Drug NameBPX-701

Drug Alias NameBPX-701

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionImmunostimulantsT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsUveal melanomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesLeiden University Medical Center

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBellicum Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsUveal melanomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A